期刊
ONCOIMMUNOLOGY
卷 3, 期 5, 页码 -出版社
LANDES BIOSCIENCE
DOI: 10.4161/onci.28977
关键词
CD1; NKT cells; tumor immunity; immunotherapy
资金
- NIAID NIH HHS [R01 AI043407] Funding Source: Medline
Type II natural killer T (NKT) cells in cancer immunity are typically associated with suppression of tumor immunosurveillance through secretion of IL-13. We previously demonstrated that CpG oligonucleotide therapy activated Type II NKT cells to produce T helper type 1 (Th1) rather than T helper type 2 (Th2) cytokines. This cytokine skewing may manifest in Type II NKT cell antitumor properties in an immunotherapeutic setting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据